Yes to AIDS drug

PUB. DATE

October 1991

SOURCE

New Scientist;10/19/91, Vol. 132 Issue 1791, p15

SOURCE TYPE

Periodical

DOC. TYPE

Article

ABSTRACT

Reports on the U.S. and Canadian health authorities' joint approval of a second AIDS drug called didanosine of ddl developed by Bristol-Myers Squibb Co. Evidence that ddl helps maintain higher levels of certain white blood cells which HIV attacks; Estimated annual cost of ddl treatment per patient; Comparison with AZT.

ACCESSION #

10557700

Related Articles

Focuses on the battle between Glaxo Wellcome and Britol-Myers Squibbs over market share for their drugs used to combat AIDS. Glaxo's nucleoside reverse transcriptase inhibitor known as AZT; Bristol-Meyers' introduction of Zerit; Sales figures; The success of Bristol in marketing its drug.

The article reports on the approval of the antiretroviral HIV/AIDS drug Atripla from Bristol-Mayers Squibb by the U.S. Food and Drug Administration. When the first antiretroviral HIV/AIDS drugs were approved by the Food and Drug Administration 10 years ago, many patients were taking more than 20...

Reports that a single pill once a day to treat HIV is the goal set by Bristol-Myers Squibb and Gilead Sciences which have agreed to collaborate. Bristol-Myers Squibb as producer of Sustiva, a non-nucleoside reverse transcriptase inhibitor; Gilead Sciences as producer of Viread and Emtriva, two...

Reports on the decision of Bristol-Myers Squibb company to abandon a lawsuit filed by AIDS activists in Thailand against its patent on an AIDS drug in 2004. Argument raised by the activists; Reason behind the company's move.

The article presents analyzes the competition between several pharmaceutical companies that develop HIV drugs. The companies Tibotec and Gilead Inc., that are launching new HIV drugs, TMC278 and elvitegravir respectively, are expected to compete with Bristol-Myers Squibb Co.'s Sustiva, and Merck...

Focuses on the packaging of the Ban, clear soft solid antiperspirant/deodorant, by Bristol-Myers Squibb. Comments from Ken Laing, senior project engineering manager at Bristol-Myers; What discovery did Laing make; Description of the features of this product.